新型冠状病毒肺炎（COVID-19）：抗病毒药物、抗体研发与中医药。
COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
机构信息
Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.
Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou, 510632, Guangdong, China.
出版信息
Virol Sin. 2020 Dec;35(6):685-698. doi: 10.1007/s12250-020-00297-0. Epub 2020 Sep 30.
The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19) is the first pandemic caused by coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no effective anti-SARS-CoV-2 drug approved worldwide for treatment of patients with COVID-19. Therapeutic options in response to the COVID-19 outbreak are urgently needed. To facilitate the better and faster development of therapeutic COVID-19 drugs, we present an overview of the global promising therapeutic drugs, including repurposing existing antiviral agents, network-based pharmacology research, antibody development and traditional Chinese medicine. Among all these drugs, we focus on the most promising drugs (such as favipiravir, tocilizumab, SARS-CoV-2 convalescent plasma, hydroxychloroquine, Lianhua Qingwen, interferon beta-1a, remdesivir, etc.) that have or will enter the final stage of human testing-phase III-IV clinical trials.
世界卫生组织（WHO）已宣布 2019 年冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的首次冠状病毒大流行。目前，全球尚无批准用于治疗 COVID-19 患者的有效抗 SARS-CoV-2 药物。迫切需要针对 COVID-19 爆发的治疗方法。为了促进治疗 COVID-19 药物的更好和更快发展，我们概述了全球有前途的治疗药物，包括重新利用现有的抗病毒药物、基于网络的药理学研究、抗体开发和中药。在所有这些药物中，我们专注于最有前途的药物（如法匹拉韦、托珠单抗、SARS-CoV-2 恢复期血浆、羟氯喹、连花清瘟、干扰素 beta-1a、瑞德西韦等），这些药物已经或即将进入 III-IV 期临床试验的最后阶段。
Zotero 插件